AbbVie Inc.
AbbVie Announces Significant Impairment Charge for Emraclidine Asset
Summary
AbbVie Inc. announced on January 9, 2025, that it will record a non-cash after-tax intangible asset impairment charge of approximately $3.5 billion related to the emraclidine asset acquired in the Cerevel Therapeutics acquisition. This follows the failure of Phase 2 EMPOWER trials for emraclidine to meet their primary endpoints in treating schizophrenia. AbbVie continues to evaluate the remaining intangible assets valued at approximately $3.6 billion.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement